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ABSTRACT
Hedonic and homeostatic hunger represent two different forms of eating: just for pleasure or
following energy deprivation, respectively. Consumption of food for pleasure was reported to be
associated with increased circulating levels of both the orexigenic peptide ghrelin and some
specific endocannabinoids in normal-weight subjects and patients with morbid obesity. To date,
the effects of palatable food on these mediators in Prader–Willi syndrome (PWS) are still
unknown. To explore the role of some gastrointestinal orexigenic and anorexigenic peptides
and endocannabinoids (and some related congeners) in chocolate consumption, we measured
changes in circulating levels of ghrelin, cholecystokinin (CCK), peptide YY (PYY), anandamide
(AEA), 2-arachidonoyl-glycerol (2-AG), palmitoylethanolamide (PEA) and oleoylethanolamide
(OEA) in eight satiated adult PWS patients after consumption of chocolate and, on a separate
day, of a non-palatable isocaloric food with the same macronutrient composition. Evaluation of
hunger and satiety was also performed by visual analogic scale. The anticipatory phase and the
consumption of food for pleasure were associated with decreased circulating levels of PYY. An
increase in PEA levels was also observed. By contrast, circulating levels of ghrelin, CCK, AEA, 2-AG
and OEA did not differ before and after the exposure/ingestion of either chocolate or non-
palatable foods. Hunger and satiety were similar in the hedonic and non-palatable sessions. In
conclusion, when motivation to eat is promoted by highly palatable foods, a depressed post-
prandial PYY secretion is observed in PWS. Although preliminary, these findings seem to
hypothesize a possible role of PYY agonists in the management of PWS patients.
Abbreviations: AEA, Anandamide; 2-AG, 2-arachidonoyl-glycerol; CB1, cannabinoid receptor type
1; OEA, oleoylethanolamide; PEA, palmitoylethanolamide; PWS: Prader-Willi syndrome; VAS, visual
analog scales
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Introduction
In animals and humans, eating is stimulated not only
by the need to restore energy homeostasis (homeostatic
hunger), but also by the rewarding properties of highly
palatable foods, mainly fatty and/or sugar-sweet meals,
despite a state of satiety and positive energy balance
(hedonic hunger) [1]. Scientific interest is focused on
investigating the physiological and pathophysiological
mechanisms underlying hedonic hunger in order to
characterize new pharmacological targets to counteract
obesity and other eating disorders.
Animal studies have demonstrated that homeostatic
and hedonic eating are regulated by different, although
overlapping, neural pathways (at central level) and
hormonal responses (at peripheral level), which involve
several appetite-regulating substances [2,3]. A huge
number of gastrointestinal endocrine cells produces
and secretes satiety hormones in response to food
consumption and digestion. These hormones, includ-
ing cholecystokinin (CCK), peptide YY (PYY) and
glucagon-like peptide 1 (GLP-1), suppress homeostatic
hunger and promote satiety [4]. In addition to these
anorexigenic peptides, there is an orexigenic peptide
produced by the stomach, named ghrelin, which is
capable to stimulate not only homeostatic, but also
hedonic hunger [5,6]. These effects are mediated by
activation of the receptor, GHS-R1a, which is expressed
not only in the hypothalamus (controlling homeostatic
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hunger), but also in tegmental and mesolimbic areas
(involved in food-related reward) [5].
Food intake is also stimulated by the endocannabi-
noids anandamide (AEA) and 2-arachidonoyl-glycerol
(2-AG), two lipid mediators that act mainly at central
level by activating the cannabinoid type 1 (CB1) recep-
tors, which in turn are widely distributed in several
brain areas, including those involved in the homeo-
static and hedonic control of feeding [7,8].
Hedonic hunger has been also investigated in
humans. In this context, Monteleone et al. [9–11]
showed that normal-weight, healthy subjects, when
administered with palatable food, exhibited increased
circulating levels of both ghrelin and 2-AG, and that
this post-prandial response was disrupted in women
with anorexia nervosa, an eating disorder associated
with altered secretion of many appetite-regulating sub-
stances. In another work, circulating levels of CCK
were reported to be decreased when normal-weight
healthy subjects were exposed to palatable food [12].
Furthermore, Rigamonti et al. [13] demonstrated that
patients with essential morbid obesity exhibited
increased circulating levels of ghrelin, AEA and 2-AG
after anticipation and consumption of chocolate, with
no differences in PYY and GLP-1 concentrations.
Again in obese individuals, Monteleone et al. [14]
reported that plasma levels of 2-AG increased after
eating a favourite food, and decreased after eating the
non-favourite food; the levels of AEA, instead,
decreased progressively in non-hedonic eating, whereas
they showed a decrease only immediately after the
exposure to the favourite food, followed by a subse-
quent increase towards pre-meal levels.
Prader–Willi syndrome (PWS) is a neurogenetic
disorder, characterized, in addition to other clinical
signs and symptoms, by hyperphagia resulting in severe
obesity in adolescence and adulthood if no strict diete-
tic control is adopted in association with modifications
in life style [15,16]. Several clinical studies have been
carried out in PWS patients to understand the patho-
physiological mechanisms underlying the hyperphagic
attitude and, particularly, to identify the presumptive
causative role of any orexigenic or anorexigenic gut
peptide.
As demonstrated by several studies, PWS children
and adults exhibit markedly elevated fasting and post-
prandial levels of ghrelin in plasma, thus suggesting
that the hypersecretion of this peptide could be impli-
cated in hyperphagia and delayed meal termination in
PWS [17–21]. However, this view seems to be contra-
dicted by the failure of ghrelin suppression to reduce
food intake in PWS [22–25]. On the contrary, only a
few studies have investigated post-prandial GLP-1,
CCK and PYY in PWS, besides reporting conflicting
results [21,26–30]. Interestingly, an unexpected
increase of the post-prandial responses of PYY and
GLP-1 to fast feeding was observed in adult PWS
patients, suggesting a potential involvement of these
anorexigenic peptides in the pathophysiology of this
eating disorder [31].
To the best of our knowledge, post-prandial concen-
trations of orexigenic and anorexigenic peptides such
as ghrelin, CCK and PYY have not been assessed in
PWS patients in the context of hedonic vs homeostatic
hunger. Additionally, to date, no one has measured
post-prandial levels of endocannabinoids in PWS
patients.
Thus, in order to investigate the potential associa-
tion of endocannabinoids and gastrointestinal peptides,
specifically, ghrelin, PYY and CCK, with hedonic eat-
ing in PWS, we have measured here changes in the
circulating levels of these appetite-regulating sub-
stances before and after the exposure to and consump-
tion of chocolate, a well-known highly palatable food,
in satiated PWS patients.
Materials and methods
Subjects
Eight male patients with PWS, aged 19–42 yr
(mean ± SD = 35.6 ± 8.3 yr), having a mean
BMI ± SD 38.8 ± 10.1 kg/m2, hospitalized for a short
period of time for periodical re-evaluation of their
clinical conditions, were enrolled into the study. The
subjects were recruited from the Division of Auxology
at Istituto Auxologico Italiano, IRCCS, Verbania, Italy.
All patients showed the typical PWS clinical pheno-
type. Cytogenetic analysis revealed interstitial deletion
of the proximal long arm of the paternally derived
chromosome 15 in all patients. All PWS subjects had
previously undergone GH treatment, withdrawn in all
cases at least 2 years before starting the study protocol.
A mild mental retardation was present in all indivi-
duals and, in this respect, the requirement for partici-
pating in the study was a score over the cut-off value of
24 in the Mini Mental State Examination (MMSE) [32].
Each participant enrolled in the study was requested
to fulfil the following conditions:
(1) to positively respond to the following
question:‘Is chocolate one of your most favorite
foods that you would eat also when satiated, just
for pleasure?’;
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(2) to give a palatability score ≥8 for chocolate,
being the administered scale ranging from 0
(not palatable) to 10 (maximally palatable).
Exclusion criteria included previous diagnosis of any
disease affecting the endocrine system and metabolism
(apart from PWS), chronic use of medications affecting
metabolism and/or appetite, ≥5.0 kg weight change
during the 3 months preceding study participation,
and allergies to or stated dislike of the components of
the test meal (see below), None of the subjects was a
marijuana smoker, an alcohol consumer or heavy
cigarette smoker, conditions known to affect circulat-
ing levels of endocannabinoids.
All participants were fully informed of the nature
and procedures of the study. Therefore, each subject
was aware that, in the first session of the experimental
protocol, he would have eaten chocolate.
Study design
The experiment used a within-subject repeated-mea-
sure design in which each volunteer served as his own
control, identical to that used by Rigamonti et al. [12].
All subjects were tested two times with an interval in-
between the tests of at least 7 days. A single-blind latin-
square crossover design could not be applied because
of the experimental needs of evoking the anticipatory
effect of palatable food and of administering a non-
palatable food with the same macronutrients and cal-
ories of the consumed palatable food (see below).
On the first test session, participants arrived at our
Clinical Investigation Unit at 08.30 h after a 12-h fast.
At 09.00 h, they were asked to rate their hunger and
satiety on visual analogue scales (VAS) that used a 10-
cm line with labels at the extremities indicating the
most negative and the most positive ratings; immedi-
ately afterwards, an iv catheter was inserted into an
antecubital vein to collect a first blood sample (time
(T) = 0); the catheter was connected to a saline solu-
tion, which was slowly infused to keep it patent
through the entire experimental session. Then, the
subjects received a breakfast of 200 kcal, with 77%
carbohydrates, 10% proteins and 13% fats.
Immediately after breakfast (consumed within
10 min), they rated again their hunger and satiety by
means of VAS. Further blood samples were drawn
(T10 and T30 at 10 min and 30 min, respectively).
After 1 h from the start of the study, the subjects
were told that they would receive chocolate.
Immediately afterwards, each participant was exposed
to the palatable food for 10 min. During this time, he
could smell and see the food but could not eat it. At the
end of the exposure, each participant was asked to rate
his hunger, satiety by means of VAS. Blood samples
were drawn at 60 min and 70 min (i.e. T60 and T70).
Then, the subject was free to eat the palatable food (see
below for details) within 10 min. Additional blood
samples were drawn immediately after the exposure
to the palatable food (T80) and at 100 min (T100),
130 min (T130), 160 min (T160) and 190 min (T190);
at the same time points, they rated again their hunger
and satiety by means of VAS.
At the end of the session, the amount of food eaten by
each participant was calculated by weighing the residual
food and subtracting it from the initial amount of food
provided, and then the calories eaten were calculated.
On the second test session, carried out at least 7 days
later, participants underwent the same experimental pro-
cedures of the first experimental session except for the fact
that they were exposed to non-palatable food and had to
eat an amount of it with the same macronutrient compo-
sition and an equal quantity of calories as the palatable
food they ate in the previous session within 10 min.
During the food exposure (specifically, from T60 to
T70), a total of 20 pictures of chocolate-made foods and
of landscapes and nature were shown in the session with
chocolate and non-palatable food, respectively.
Palatable and non-palatable foods
The palatable food was a milk-chocolate tablet
(200 g for a total of 1000 kcal with 61.4% carbohy-
drates, 7.9% proteins, and 30.7% fat), served in a dish
from which the subject was free to eat until he became
satiated (for a maximum corresponding to the whole
chocolate tablet).
The non-palatable food, which was identified by all
participants as non-desirable just for pleasure (specifi-
cally, with a palatability score <2) consisted of bread
and butter, which were combined ad hoc to provide the
same macronutrients and calories of the consumed
chocolate. Calorie and nutrient contents of palatable
and non-palatable foods were calculated by using the
information reported on the labels of each packaged
food (chocolate tablet and butter). To calculate calorie
and nutrient content of bread, we obtained the recipe
from the baker who made it.
To maintain a stable daily caloric intake of the in-
hospital PWS patients, the amount of foods adminis-
tered at lunch and dinner of the experimental days was
proportionally reduced to account for the calories of
the test meals (i.e. chocolate or non-palatable food).
Evaluation of body composition
Anthropometric characteristics were evaluated during
the screening period. BMI was calculated from
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measured height and weight. Fat-free mass (FFM) and
fat mass (FM) were evaluated by bioelectrical impe-
dance analysis (Human-IM Scan, DS-Medigroup,
Milan, Italy).
Blood sampling and biochemical measurements
Blood was collected in tubes with or without antic-
oagulant (EDTA). Plasma or serum was separated by
centrifugation and stored at −20 C.
Total plasma ghrelin level, including both octanoy-
lated and des-octanoylated ghrelin, was measured by a
commercially available RIA (Millipore, Saint Charles,
MO, USA). The sensitivity of the method was 93 pg/ml;
intra- and interassay coefficients of variation (CVs) were
10.0 and 14.7% respectively. The concentration range was
10,496–6718 pg/ml and the recovery percentage 90%.
Total plasma PYY level, including both PYY1-36 and
PYY3–36, was measured by a commercially available RIA
(Millipore, Saint Charles, MO, USA). The sensitivity of
the method was 10 pg/ml; intra- and interassay CVs were
2.9 and 7.1% respectively. The concentration range was
1117–1430 pg/ml and the recovery percentage 96%.
Serum CCK, precisely CCK6–33 solphate (100%
cross-reactivity), was measured by a commercially
available radioimmunoassay kit (EuroDiagnostica,
Malmö, Sweden) after an extraction procedure, as indi-
cated in the instructions provided by the manufacturer.
The sensitivity of the method was 0.3 pmol/l; intra- and
interassay CVs were 5.5 and 13.7%, respectively. The
concentration range was 0,78–25 pmol/l and the recov-
ery percentage 80%.
Serum insulin concentration was determined by
chemiluminescent immunometric assay using a com-
mercial kit (Immulite 2000, DPC, Los Angeles, CA,
USA). The sensitivity of the method was 2 µIU/ml;
intra- and interassay CVs were 22–38% and 14–23%,
respectively.
Serum glucose level was measured by the glucose oxi-
dase enzymatic method (Roche Diagnostics, Monza, Italy).
Plasma levels of AEA, 2-AG, oleoylethanolamide
(OEA) and palmitoylethanolamide (PEA) were deter-
mined by isotopic dilution-liquid chromatography-
mass spectrometry, as described previously [13].
Statistical analysis
As conventionally established, the sample size was
determined for giving 80% power at the .05 level of
significance (two-sided). The expected mean difference
of circulating levels of ghrelin 20 min after exposure to
palatable vs non-palatable food (200 pg/ml) and the
estimated standard deviation of the same variable
(150 pg/ml)) were deducted by the results reported in
the work by Rigamonti et al. [13].
The Sigma Stat 3.5 statistical software package was
used for data analysis. GraphPad Prisma 5.0 software
was used for plotting data.
The Shapiro–Wilk test showed that all parameters
were normally distributed.
Results are reported as mean ± SD (standard devia-
tion). The responses in glucose, insulin, ghrelin, PYY,
CCK, AEA, 2-AG, PEA, OEA and VAS scores for
hunger and satiety were evaluated as absolute values
for each experimental session of eating (breakfast + cho-
colate and breakfast + non-palatable).
All parameters (ghrelin, PYY, CCK, VAS scores for
hunger and satiety, glucose and insulin) were compared
within eachexperimental sessionof eating (breakfast+ cho-
colate and breakfast + non-palatable-food) over sampling
times (intra-group analysis) and between the two experi-
mental sessions of eating for any sampling time (inter-
group analysis) by using a two-way ANOVAwith repeated
measures (with the two factors time and session and the
interaction time × session), followed by the post hoc
Bonferroni’s test, which was used to compare responses
after breakfast (i.e. T10, T30 and T60 vs 0 min) and the
responses after chocolate or non-palatable food (i.e. T70,
T80, T100, T130, T160 and T190 vs 60 min) for both
experimental sessions of eating (i.e. breakfast + chocolate
and breakfast + non-palatable-food). The same statistical
test was applied for analysing the responses in endocanna-
binoids and related congeners (AEA, 2-AG, PEA and
OEA) only after the secondpart of the experimental session
(i.e. T70, T100, T130 and T190 vs 60 min for both experi-
mental sessions of eating). A two-way ANOVA, followed
by the post hoc Bonferroni’s test, was used to compare the
ratios of circulating ghrelin levels to those of PYY (ghrelin/
PYY) at T0 and T80 in both sessions of eating. A level of
significance of p < 0.05 was used for all data analyses.
Results
Body composition and other clinical information
The Table 1 reports data of body composition in our
population of PWS patients. Importantly, body weight
did not significantly change in each PWS subject, when
the first (breakfast + chocolate) and second (break-
fast + non-palatable-food) sessions of eating were com-
pared (data not shown).
Calorie ingestion
As expected, the mean values of calories and macro-
nutrients of palatable and non-palatable foods were not
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significantly different (data not shown). PWS subjects
ate 181.3 ± 25.9 g of chocolate (range: 150–200 g),
which correspond to 925.0 ± 103.5 kcal (range:
800–1000 kcal).
Circulating levels of gastrointestinal peptides:
ghrelin, PYY and CCK
Table 2 reports the statistical results of the time ×
session repeated measures ANOVA applied to each
parameter (ghrelin, PYY and CCK).
Ghrelin
Circulating levels of ghrelin did not change signifi-
cantly over the sampling times and between the two
experimental sessions of eating (Figure 1).
PYY
There was a statistically significant increase in circulat-
ing levels of PYY at 30 and 60 min (vs 0 min after the
breakfast, p < 0.01) and at 80, 100 and 160 min after
non-palatable food in PWS patients administered with
the breakfast + non-palatable session, whereas no such
difference was found in those administered with the
breakfast + chocolate session (intra-group analysis).
Furthermore, the PWS subjects, tested with the hedo-
nic session, when compared with the non-palatable
session, exhibited significantly lower plasma concentra-
tions of PYY at 30, 60, 80, 100 and 160,min (p < 0.01)
(inter-group analysis) (Figure 1).
CCK
Circulating levels of CCK did not change significantly
over sampling times and between the two experimental
sessions of eating (Figure 1).
Table 1. Demographic and clinical characteristics of the PWS
subjects enrolled in the study.
PWS Subjects
Number (n.) 8
Age (yrs) 35.6 ± 8.3
BMI (kg/m2) 38.8 ± 10.1
FFM (kg) 55.3 ± 11.4
FFM (%) 58.7 ± 3.8
FM./kg) 39.5 ± 12.1
FM (%) 41.3 ± 3.8
PWS = Prader–Willi syndrome; BMI = body mass index; FM = free fat mass;
FM = fat mass.
Table 2. Statistical results of the time × session repeated
measures ANOVA applied to each variable investigated.
Factor
Variable Time Session Time × Session
Ghrelin F(9/54)=1.32 F(1/6)=0.97 F(9/54)=1.47
CCK F(4/24)=1.98 F(1/6)=0.56 F(4/24)=1.92
PYY F(9/54)=6.32* F(1/6)=3.82* F(9/54)=1.08*
2-AG F(4/24)=2.03 F(1/6)=1.24 F(4/24)=1.58
AEA F(4/24)=3.22* F(1/6)=1.08 F(4/24)=1.68
PEA F(4/24)=0.96 F(1/6)=2.43* F(4/24)=2.11
OEA F(4/24)=3.17 F(1/6)=1.09 F(4/24)=1.14
Hunger F(9/54)=3.98* F(1)=2.15 F(9/54)=2.78
Satiety F(9/54)=3.04* F(1/6)=2.01 F(9/54)=2.88
Glucose F(9/54)=2.69* F(1/6)=1.15 F(9/54)=2.02
Insulin F(9/54)=3.06* F(1/6)=0.98 F(9/54)=2.14
*: p<0.05.
Figure 1. Changes of circulating levels of ghrelin (top panel),
CCK (middle panel) and PYY (bottom panel) in PWS patients
after breakfast (at the left of the dotted vertical line, i.e. T0-T70)
and chocolate or non-palatable meal (at the right of the dotted
vertical line, i.e. T70-T190) during the hedonic and non-palatable
sessions of eating, respectively. Breakfast was consumed from T0
to T10, while chocolate or non-palatable meal from T70 to T80
after a sensorial exposure of the foods and view of pictures of
chocolate-made foods (in the hedonic session) or landscapes
and nature (in the non-palatable session) from T60 to T70. See
the text for further details. Values are expressed as mean ± SD. *
p < 0.05 vs the corresponding time point of the non-palatable
session; × p < 0.05 vs the corresponding T0 or T60 value.
FOOD & NUTRITION RESEARCH 5
Ratio ghrelin/PYY
There was no statistically significant difference in the
ratio ghrelin/PYY at T0 among PWS patients admi-
nistered with breakfast + chocolate or break-
fast + non-palatable-food. On the contrary, the ratio
ghrelin/PYY at T80 was significantly higher than that
at T0 during hedonic eating (p < 0.05) and at the same
time point after non-palatable food (p < 0.05).
Although not statistically significant, the ratio ghre-
lin/PYY at T80 after non-palatable food was lower
than that at T0 during the same session of eating
(Figure 2).
Circulating levels of endocannabinoids and related
mediators: AEA, 2-AG, PEA and OEA
Table 2 reports the statistical results of the time ×
session repeated measures ANOVA applied to each
parameter (AEA, 2-AG, PEA and OEA).
AEA
There was a statistically significant decrease in circulat-
ing levels of AEA at 100, 130 and190 min (vs 60 min,
p < 0.05) in PWS patients administered with the break-
fast + chocolate session and also with the break-
fast + non-palatable-food session (intra-group
analysis), with no difference between the two sessions
(inter-group analysis); (Figure 3).
2-AG
Circulating levels of 2-AG did not change significantly
over sampling times and between the experimental
sessions of eating (Figure 3).
PEA
Circulating levels of PEA were significantly higher at
100 and 190 min in PWS patients administered with
the breakfast + chocolate session than the break-
fast + non-palatable session (p < 0.05) inter-group
analysis), with no significant time-related changes
(intra-group analysis); (Figure 3).
OEA
Circulating levels of OEA did not change significantly
over sampling times and between the experimental
sessions of eating (Figure 3).
VAS scores: hunger and satiety
Table 2 reports the statistical results of the time × session
repeated measures ANOVA applied to each parameter
(hunger and satiety).
Hunger
There was a statistically significant decrease in hunger
VAS scores at 10, 30 and 60 min (vs 0 min after the
breakfast, p < 0.01) for both experimental sessions and
at 80, 100, 130, 160 and 190 min (vs 60 min after the
chocolate or non-palatable food in PWS patients admi-
nistered with the breakfast + chocolate and the break-
fast + non-palatable-food sessions, respectively (intra-
group analysis), with no difference between the two
sessions (inter-group analysis)) (Figure 4).
Satiety
There was a statistically significant increase in satiety
VAS scores at 10, 30 and 60 min (vs 0 min after the
breakfast, p < 0.01) for the breakfast + chocolate and
breakfast + non-palatable-food sessions and at 80, 100,
Ghrelin / PYY
T0 T80
0
2
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10
CHOCOLATE
NON-PALATABLE FOOD
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Figure 2. Ratios of circulating ghrelin levels to those of PYY (ghrelin/PYY) at T0 and T80 in PWS patients administered with
breakfast + chocolate or breakfast + non-palatable-food. Values are expressed as mean ± SD. * p < 0.05 vs T80 of the non-palatable
session; × p < 0.05 vs T0 of the hedonic session.
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130, 160 and 190 min (vs 60 min after the chocolate or
non-palatable food) for both sessions (intra-group ana-
lysis), with no difference between the two sessions
(inter-group analysis) (Figure 4).
Metabolic parameters: glucose and insulin
Table 2 reports the statistical results of the time ×
session repeated measures ANOVA applied to each
parameter (glucose and insulin).
Glucose
Administration of both experimental sessions of eating
(i.e. breakfast + chocolate or breakfast + non-palatable-
food) evoked an identical statistically significant
increase in glucose concentrations at 30 and 60 min
(vs 0 min after breakfast, p < 0.01) (intra-group analy-
sis), with no difference between the two sessions (inter-
group analysis) (Figure 5).
Insulin
Administration of both experimental sessions of eating
(i.e. breakfast + chocolate or breakfast + non-palatable-
food) evoked an identical statistically significant
increase in insulin concentrations at 10, 30 and
60 min (vs 0 min after breakfast, p < 0.01) (intra-
group analysis), with no difference between the two
sessions (inter-group analysis) (Figure 5).
Discussion
Themain finding of the present study carried out in PWS
patients was that circulating levels of PYY were persis-
tently found depressed during the entire hedonic session
(breakfast + palatable-food session), which included the
administration of a satiating breakfast and, one hour
after, a chocolate tablet, which was initially served for
stimulating an intense sensorial experience and then
freely eaten. By contrast, increased PYY secretion was
observed during the breakfast + non-palatable-food ses-
sion, in which the chocolate tablet was replaced by an
isoenergetic non-palatable meal with the same macronu-
trient composition (i.e. bread and butter). It is note-
worthy that during the breakfast+ non-palatable-food
session, two statistically significant peaks in circulating
PYY levels occurred after breakfast (at T30-T60) and
non-palatable food (at T80-T100), being the second
response in PYY higher than the first one presumably
because of the more caloric content in the non-palatable
food than in the breakfast. The blunted PYY secretion in
our PWS subjects, observed in the hedonic session of
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Figure 3. Changes of circulating levels of anandamide (AEA, top left panel), 2-arachidonoyl-glycerol (2-AG, top right panel),
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(i.e. T60-T70) and after (i.e. T60-T190) chocolate or non-palatable meal during the hedonic and non-palatable sessions of eating,
respectively. Chocolate or non-palatable meal was consumed from T70 to T80 after a sensorial exposure of the foods and view of
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eating, was (perhaps) already present at T0 before starting
the experiment.
In our PWS subjects, the persistent inhibition of
PYY secretion during the entire hedonic session likely
reflects the orexigenic state occurring in the cephalic
phase (or, alternatively, the anticipatory phase) before
consumption of highly palatable food, when all (both
lean and obese) individuals think about, see and/or
smell the food but do not eat it yet [33]. The antici-
patory effect of highly palatable food is, obviously, a
crucial aspect of our experimental protocol: specifically,
the participants in the present study knew that they
would have eaten chocolate in the first experimental
session, because of our need to balance the caloric
content and macronutrient composition of the non-
palatable food to that of the palatable one (see also
‘Materials and methods’). However, at the beginning
of the hedonic session of eating and after the exposure
to the palatable food, such blunted PYY secretion
seems to be a distinctive ‘paradoxical’ response in
PWS, which is not present in lean subjects and patients
with essential morbid obesity [9,13]). In fact, different
from these individuals, who underwent a similar pro-
tocol, based on the findings obtained in the present
study one might hypothesise that PWS subjects, who
were aware that they would have eaten chocolate in
that day, and, hence, were likely to experience an
intense sensorial exposure to this palatable food (T60-
T70), showed an inhibited PYY secretion possibly to
facilitate the ensuing ingestion of pleasurable food (i.e.
chocolate) and to block an early meal termination.
Paradoxically, this secretory pattern of PYY (i.e. the
blunted PYY secretion) might be the only mechanisms
through which PWS patients can eat for pleasure. In
fact, PWS individuals have been demonstrated in many
clinical studies to exhibit higher (fasting and post-
prandial) ghrelin levels than lean subjects or patients
with essential morbid obesity [17–21], levels that can-
not increase further following exposure to palatable
food.
This argumentation is supported by the present
study showing no significant changes in ghrelin secre-
tion throughout the entire protocol, a not surprising
finding since circulating levels of ghrelin were reported
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Figure 4. Changes of VAS ratings of hunger (top panel) and satiety (bottom panel) in PWS patients after breakfast (at the left of the
dotted vertical line, i.e. T0-T70) and chocolate or non-palatable meal (at the right of the dotted vertical line, i.e. T70-T190) during
the hedonic and non-palatable sessions of eating, respectively. Breakfast was consumed from T0 to T10, while chocolate or non-
palatable meal from T70 to T80 after a sensorial exposure of the foods and view of pictures of chocolate-made foods (in the hedonic
session) or landscapes and nature (in the non-palatable session) from T60 to T70. See the text for further details. Values are
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to be not suppressed by food intake in PWS adults
[17,20].
Rather than considering either PYY or ghrelin as
single biochemical parameter, the ratio ghrelin/PYY
seems to be of more relevant endocrinological and
also pharmacological interest. In fact, in the present
study, the ratio ghrelin/PYY at T80 after chocolate,
which corresponds to the climax of the hedonic experi-
ence, was higher than that at the same time point after
non-palatable food, confirming the occurrence of an
orexigenic state in PWS patients administered with a
palatable food (see also above). The ratio ghrelin/PYY
(high for decreased PYY levels and/or increased ghrelin
levels) might be a correlate of activation of the hedonic
pathway of food intake. Although it might be proposed
as a marker of development of hyperphagia in PWS,
with important clinical and therapeutic implications,
further studies are mandatory to confirm these intri-
guing hypotheses.
A limitation of the present study, however, concerns
the lack of evaluation of des-octanoylated ghrelin
(UAG). In fact, UAG is known to induce a negative
energy balance by decreasing food intake and delaying
gastric emptying via the hypothalamus [34].
Concerning our findings, further investigation
isneeded, in order to better understand the role of the
different forms of circulating ghrelin in hedonic eating
in PWS.
Unexpectedly, in the present study, only a slow
progressive increase in CCK secretion (not significant)
was found after the second part of the two sessions of
eating, without any difference between consumption of
palatable and non-palatable meals. Few clinical studies
have investigated the effects of a meal on CCK secre-
tion in PWS, reporting conflicting results when com-
pared to a control group [29,35–37]. Nevertheless,
Monteleone et al. [12] have demonstrated that, in
satiated normal-weight subjects, there is no post-pran-
dial increase in circulating levels of CCK after admin-
istration of palatable food, suggesting that eating for
the rewarding properties of a highly pleasurable food is
also promoted by an absent or insufficient CCK-
mediated ‘anorexigenic brake’. To date, we are not
aware of the exact reason of the unchanged circulating
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Figure 5. Changes of circulating levels of glucose (top panel) and insulin (bottom panel) in PWS patients after breakfast (at the left
of the dotted vertical line, i.e. T0-T70) and chocolate or non-palatable meal (at the right of the dotted vertical line, i.e. T70-T190)
during the hedonic and non-palatable sessions of eating, respectively. Breakfast was consumed from T0 to T10, while chocolate or
non-palatable meal from T70 to T80 after a sensorial exposure of the foods and view of pictures of chocolate-made foods (in the
hedonic session) or landscapes and nature (in the non-palatable session) from T60 to T70. See the text for further details. Values are
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FOOD & NUTRITION RESEARCH 9
levels of CCK in our PWS patients tested with the non-
palatable food, such as reduced caloric content or
inappropriate macronutrient composition of the admi-
nistered (palatable or non-palatable) meals, few sam-
pling times or methodological differences in CCK
assay. Therefore, any speculation regarding the role of
CCK in hedonic eating in PWS should await further
clinical studies on this issue, taking also into account
the availability of CCK agonists in pre-clinical pharma-
cological research [38].
In the present study, hunger and satiety VAS scores
were congruent with ingestion of meals (breakfast or
palatable/non-palatable food). We would have expected
lower and higher values in hunger and satiety VAS
score, respectively, after hedonic than non-palatable
session, being PYY secretion depressed. However, this
was not the case. A possible reason of this discrepancy
may be the subjective measurement of these parameters
(which are probably more strongly influenced also by
the syndrome itself), as well as the wide variability and
scarce reproducibility associated with any experimental
method to measure appetite [39].
Different from the results obtained in lean subjects
[9] and patients with essential morbid obesity [13,14],
the findings of the present study do not point to an
important role of the endocannabinoids AEA and 2-
AG, and of the non-endocannabinoid AEA congener,
OEA, in the modulation of hedonic eating in PWS.
Specifically, in our study circulating levels of AEA, 2-
AG and OEA were not significantly different between
the two sessions with the exposure to chocolate or non-
palatable food. By contrast, circulating levels of PEA
were significantly higher at T100 and T190 in PWS
patients administered with chocolate than non-palata-
ble food. Finally, there was a significant decrease of
circulating levels of AEA at T100, T130 and T190 in
both sessions (i.e. breakfast + chocolate and break-
fast + non-palatable-food), without any time-related
differences for the other compounds 2-AG, PEA and
OEA. These negative data regarding the endocannabi-
noids AEA and 2-AG are, however, in agreement with
the lack of changes in ghrelin levels in hedonic eating
in PWS patients, as discussed above, thus corroborat-
ing previous evidence on the existence of direct corre-
lations between ghrelin secretion and endocannabinoid
production [9,13]. They might also indicate the lack of
any cross-talk between endocannabinoids and PYY,
whose levels in our previous study in essential obese
volunteers [13] did not change.
To date, there is scarce evidence that the peroxisome
proliferator-activated receptor α (PPAR-α) and the two
PPAR-α ligands OEA and PEA are implicated in the
rewarding effects associated with food intake [40].
Therefore, it is difficult to interpret the statistically
significant increase of circulating levels of PEA in
PWS after exposure to chocolate, when compared to
those in breakfast + non-palatable-food session. We
can only speculate that, particularly at T190, when
this increase was stronger, this response might repre-
sent an adaptive mechanism to counteract, via activa-
tion of PPAR-α, the peripheral inflammatory and
metabolic (i.e. steatosis) consequences of exaggerated
hedonic eating. These results are different from those
reported in the study by Monteleone et al. [9,14] in
normal-weight and obese subjects, respectively, in
whom circulating levels of OEA and PEA were found
to be similar following consumption of either favourite
or non-favourite food, whereas in the study by
Rigamonti et al. [13], carried out in patients with
essential morbid obesity, circulating levels of OEA,
but not PEA, were significantly higher at T60 before
exposure to chocolate. Further studies in animals and
humans are mandatory to understand the physiological
role and the pathophysiological implications of endo-
genous PPAR-α ligands, including PEA and OEA, in
food intake and, generally, reward.
Finally, in the present study the decline of circulat-
ing levels of AEA after ingestion of palatable or non-
palatable food, already described by Rigamonti et al.
[13] in patients with essential morbid obesity, might be
due to circadian changes in the levels of this com-
pound, previously demonstrated in the rat brain [41].
Alternatively, since PWS patients were still insulin-
responsive, this finding is more likely due to post-
prandial insulin-induced inhibition of plasma AEA
levels, already observed by Di Marzo et al. [42].
Conclusions
Clearly different from normal-weight healthy subjects
[9] and patients with essential morbid obesity [13,14],
when motivation to eat is generated by the availabil-
ity of highly palatable food and not just by food
deprivation, a depressed post-prandial PYY secretion,
at least theoretically able to re-activate central
rewarding system, was found in PWS patients. In
this context, the role of total ghrelin and endocanna-
binoids seems to be negligible. Taking into account
these preliminary observations, while patients suffer-
ing from essential morbid obesity might actually be
treated with ghrelin receptor and CB1 neutral antago-
nists in order to block hyperphagia induced by pala-
table foods, the use of PYY agonists appears to be
instead one of the most appropriate pharmacological
strategy in PWS, allowing to reinforce the insufficient
post-prandial anorexigenic response when PWS
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patients are exposed to palatable foods [31]. Although
the present report should be considered preliminary,
it might serve as a pilot study to be validated in
future studies with larger cohorts.
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